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Virus, Strain, and Epitope Specificities of Neutralizing Bovine Monoclonal
Antibodies to Bovine Herpesvirus 1 Glycoproteins gB, gC, and gD, with
Sequence and Molecular Model Analysis
Abstract
Three bovine monoclonal antibodies (BomAb) raised to bovine herpesvirus (BoHV) 1.1 and specific for the
viral glycoproteins gB, gC, and gD were tested for reactivity to two isolates of BoHV-1.1, one of BoHV-1.2,
and two of BoHV-5 in virus neutralization and indirect fluorescent antibody assays. They were also tested with
other herpesviruses infecting cattle and other mammalian alphaherpesviruses, and found negative or of
negligible reactivity. Their BoHV-1.1 epitope specificity was examined using competitive ELISA with
peroxidase-labeled murine monoclonal antibodies (MumAb) that had been previously characterized. To
explain the incongruities observed, the amino acid sequences of the epitopes and adjacent regions of
BoHV-1.1, 1.2, and 5 were compared, and molecular modeling was performed using human herpesvirus 1
glycoprotein crystals as templates. The anti-gB BomAb reacted strongly with BoHV-1.1 and BoHV-1.2, and
poorly or not at all with BoHV-5. It competed with a MumAb specific for a BoHV-1.1 gB epitope previously
shown to only partially cross-react between BoHV-1 and BoHV-5. BoHV-5 gB has nearly identical sequence
with BoHV-1.1 in the epitope region, but modeling suggested the lack of cross-reactivity of the MumAb was
due to masking of the epitope in BoHV-5 by an adjacent region, which has significant sequence differences
between BoHV-1.1 and BoHV-5. The BomAb reactivity could also be explained by masking, or by reactivity
with the adjacent region. The anti-gC BomAb reacted strongly with one isolate of BoHV-1.1 and BoHV-1.2,
less well with a heterologous isolate of BoHV-1.1, and poorly or not at all with BoHV-5. It did not compete
with any of the anti-gC MumAb tested, but a target domain was suggested by BoHV-1.1, 1.2, and 5 sequence
divergence. The anti-gD BomAb reacted strongly with all BoHV-1.1, 1.2, and 5 isolates tested. However, it
competed with two MumAb previously shown to not cross-react between BoHV-1.1 and BoHV-5. Sequence
analysis and modeling suggested the cross-reactivity of the anti-gD BomAb was due to it reacting with an
epitope-adjacent region or regions conserved between BoHV-1.1 and BoHV-5, but not with other
alphaherpesviruses. The results suggest the usefulness of combining in vitro biological data with sequence or
structure modeling data to investigate important epitopes involved in immunity to infectious agents.
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a  b  s  t  r  a  c  t
Three  bovine  monoclonal  antibodies  (BomAb)  raised  to  bovine  herpesvirus  (BoHV)  1.1
and  speciﬁc  for  the  viral  glycoproteins  gB, gC,  and gD  were  tested  for reactivity  to  two
isolates  of BoHV-1.1,  one  of BoHV-1.2,  and  two of  BoHV-5  in  virus  neutralization  and
indirect  ﬂuorescent  antibody  assays.  They  were also  tested  with other  herpesviruses  infect-
ing cattle  and  other  mammalian  alphaherpesviruses,  and  found  negative  or of  negligible
reactivity.  Their  BoHV-1.1  epitope  speciﬁcity  was examined  using  competitive  ELISA  with
peroxidase-labeled  murine  monoclonal  antibodies  (MumAb)  that had  been  previously
characterized.  To  explain  the  incongruities  observed,  the  amino  acid sequences  of  the
epitopes  and  adjacent  regions  of  BoHV-1.1,  1.2,  and  5 were  compared,  and molecular
modeling  was  performed  using  human  herpesvirus  1 glycoprotein  crystals  as  templates.
The  anti-gB  BomAb  reacted  strongly  with  BoHV-1.1  and  BoHV-1.2,  and poorly  or  not  at
all  with  BoHV-5.  It competed  with  a MumAb  speciﬁc  for a BoHV-1.1  gB  epitope  previ-
ously  shown  to  only  partially  cross-react  between  BoHV-1  and  BoHV-5.  BoHV-5  gB  has
nearly  identical  sequence  with  BoHV-1.1  in  the  epitope  region,  but modeling  suggested
the  lack  of cross-reactivity  of the MumAb  was  due  to  masking  of the  epitope  in  BoHV-
5  by  an adjacent  region,  which  has  signiﬁcant  sequence  differences  between  BoHV-1.1
and  BoHV-5.  The  BomAb  reactivity  could  also  be explained  by masking,  or  by  reactivity
with  the  adjacent  region.  The  anti-gC  BomAb  reacted  strongly  with  one  isolate  of  BoHV-
1.1  and  BoHV-1.2,  less  well  with  a heterologous  isolate  of BoHV-1.1,  and  poorly  or not
at  all  with  BoHV-5.  It did  not  compete  with  any  of  the  anti-gC  MumAb  tested,  but  a
target  domain  was suggested  by BoHV-1.1,  1.2,  and  5  sequence  divergence.  The anti-gD
Abbreviations: aa, amino acid; HV, alphaherpesvirus; AlHV, alcelaphine herpesvirus; BoHV, bovine herpesvirus; BomAb, bovine monoclonal antibody;
CaHV,  canid herpesvirus; cELISA, competitive ELISA; CVB, Center for Veterinary Biologics; EA, epitope-adjacent amino acid sequence; EAC, EA, carboxyl
side; EAN, EA, amino side; EHV, equid herpesvirus; FeHV, felid herpesvirus; gB, HV glycoprotein B; gC, HV glycoprotein C; gD, HV glycoprotein D; gp,
glycoprotein; HHV, human herpesvirus; HV, herpesvirus; IFA, indirect ﬂuorescent antibody; MEM, minimum essential media; MumAb, murine monoclonal
antibody; NVSL, National Veterinary Services Laboratories; RIP, radio-immunoprecipitation; SuHV, suid herpesvirus; TCID50, tissue culture infective doses
50;  VN, virus neutralization.
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BomAb  reacted  strongly  with  all BoHV-1.1,  1.2,  and 5 isolates  tested.  However,  it competed
with  two  MumAb  previously  shown  to not  cross-react  between  BoHV-1.1  and  BoHV-5.
Sequence  analysis  and  modeling  suggested  the  cross-reactivity  of  the  anti-gD  BomAb  was
due to it  reacting  with  an epitope-adjacent  region  or regions  conserved  between  BoHV-1.1
and BoHV-5,  but  not  with  other  alphaherpesviruses.  The  results  suggest  the  usefulness  of
combining  in  vitro  biological  data  with  sequence  or structure  modeling  data  to investigate
important  epitopes  involved  in  immunity  to infectious  agents.
Published  by  Elsevier  B.V.
1. Introduction
Infectious bovine rhinotracheitis virus (Madin et al.,
1956), infectious pustular vulvovaginitis virus (Greig et al.,
1958; Kendrick et al., 1958; Gillespie et al., 1959), and
bovine encephalitis virus (French, 1962; Eugster et al.,
1974) are closely related viruses isolated in the United
States. Based on molecular similarities and differences the
viruses were designated bovine herpesvirus (BoHV-) 1.1,
1.2, and 1.3, respectively (Engels et al., 1986; Metzler et al.,
1986). The bovine encephalitis herpesvirus is now recog-
nized as a separate viral species, BoHV-5 (Davison, 2010).
Increasingly reﬁned nucleic acid and immunological
techniques have been used to compare the viruses and
characterize their glycoproteins (gp) and epitopes (Misra
et al., 1981; Mayﬁeld et al., 1983; Collins et al., 1984;
Metzler et al., 1985; van Drunen Littel-van den Hurk and
Babiuk, 1985; Marshall et al., 1986; Hughes et al., 1988;
Ayers et al., 1989, 1994; van Drunen Littel-van den Hurk
et al., 1992; Rijsewijk et al., 1999; Delhon et al., 2003).
Cloning and sequencing of partial and complete individ-
ual genes allowed gp gene assignment, analysis of primary
and secondary characteristics and structures, as well
as sequence/function analysis and comparisons between
BoHV (Whitbeck et al., 1988; Fitzpatrick et al., 1989, 1990;
Tikoo et al., 1990, 1993; Abdelmagid et al., 1995; Hecht
et al., 1995; Ros and Belak, 2002; Gabev et al., 2010).
Whole genome sequences, protein sequences, muta-
tion, expression, and recombination allowed studies on
molecular processing and examination of biological differ-
ences between herpesviruses (HV) and between BoHV (Seal
and Whetstone, 1994; Schwyzer and Ackermann, 1996;
Spear et al., 2000; Delhon et al., 2003; Al-Mubarak et al.,
2004; Gabev et al., 2010). Expressed peptides and synthetic
peptides designed from sequence information allowed fur-
ther reﬁnement of epitope location (Abdelmagid et al.,
1995; Chowdhury, 1995, 1997; Rijsewijk et al., 1999).
Five viral envelope gp are involved in human her-
pesvirus 1 (HHV-1) attachment and entry: gB, gC, gD,
gH, and gL (reviewed in Spear et al., 2000; Rey, 2006).
It is believed similar mechanisms apply to all alphaher-
pesviruses (HV) except those lacking gD. The homodimer
gC ﬁrst binds to the cell membrane proteoglycans, although
binding by other gp e.g., gB and gD, can contribute to bind-
ing, and gC is not required for attachment (Engels and
Ackermann, 1996). This is followed by the homodimer
gD binding to one of a few cellular receptors that vary
by cell type and species, although the receptor members
are usually homologous (Connolly et al., 2001). The bind-
ing results in a conformational change in gD that triggers
virus envelope – cell membrane fusion by a complex of
the homotrimer gB and heterodimer gH/L. Both gB and gH
include domains consistent with fusion activity, and gL is
believed to be needed to maintain the correct structure of
gH (Heldwein et al., 2006; Roizman et al., 2007).
Crystal structures of HHV-1 gB (Heldwein et al.,
2006) and gD (Pilling et al., 1999; Carﬁ et al., 2001;
Krummenacher et al., 2005) have been determined, which
in turn allowed homologous models to be constructed for
BoHV-1.1 gB (Ros and Belak, 2002) and gD (Tikoo et al.,
1990; Goltz et al., 2006), BoHV-1.2 gD (Leung-Tack et al.,
1994), and BoHV-5 gD (Abdelmagid et al., 1995). Other
HV gp (e.g., HHV-1 gC) have been partially modeled from
crystal structures of other molecules. The determination
of the structure of HHV-1 functional domains and their
relationship to epitopes (Heldwein et al., 2006) may  also
contribute to understanding BoHV-1/5 functional regions
and epitopes.
The major HV envelope gp gB, gC, and gD are the
targets of protective cellular and humoral host immune
responses (Norrild et al., 1979; Denis et al., 1996;
Babiuk et al., 1996; Belknap et al., 1999). mAb  from
the vertebrate species usually infected may  better reﬂect
the natural immune response than the more typically
employed murine mAb  (MumAb) (Jessup et al., 2000).
They may  be preferentially directed to protection-relevant
epitopes.
This study examined the reactivity of three BoHV-1.1-
neutralizing bovine mAb  (BomAb) with isolates of the
closely related BoHV-1.1, BoHV-1.2, and BoHV-5 viruses,
the BomAb’s reactivity with other HV, as well as their
competition with well characterized MumAb  to BoHV-1.1.
Sequences and structure models of gp of the three viruses
were then accessed or generated to help explain the obser-
vations.
2. Materials and methods
2.1. Viruses
Two  BoHV-1.1 isolates (Madin et al., 1956; York et al.,
1957) were used: Cooper (also called Colorado), 107.7 tissue
culture infective dose 50 (TCID50)/ml, from a preparation
used by the Center for Veterinary Biologics (CVB) for in vivo
evaluation of infectious bovine rhinotracheitis vaccines in
cattle; and Los Angeles, 107.6 TCID50/ml, from a prepara-
tion (VR-188) obtained from the American Type Culture
Collection. One BoHV-1.2 isolate was used: K-22 (Kendrick
et al., 1958), 107.8 TCID50/ml, from a preparation kindly
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provided by C.A. Whetstone. Two BoHV-5 isolates were
used: EC-1 (Eugster et al., 1974), 108.0 TCID50/ml, and EC-2
(d’Offay et al., 1993), 107.0 TCID50/ml, each from prepara-
tions kindly provided by C.A. Whetstone. BoHV-2 (bovine
mammillitis virus), BoHV-4 (DN599 isolate, Movar virus),
alcelaphine herpesviruses 1 (AlHV-1, WC-11 strain, malig-
nant catarrhal fever virus), and 2 (AlHV-2, 840412 isolate,
hartebeest malignant catarrhal fever virus) were provided
by the National Veterinary Services Laboratories (NVSL).
Suid herpesvirus 1 (SuHV-1, pseudorabies virus), equid
herpesvirus 1 (EHV-1, equine abortion virus), felid her-
pesvirus 1 (FeHV-1, feline viral rhinotracheitis virus), and
canid herpesvirus 1 (CaHV-1) were from preparations used
by CVB for in vitro vaccine evaluation using cell culture
titration and VN assays. HHV-1 was from a preparation
obtained from the American Type Culture Collection.
2.2. Antibodies (Ab)
Ascites ﬂuid produced in nude mice of three virus neu-
tralization (VN) positive BomAb – gB-09, gC-05, and
gD-16 (Levings et al., 2014) – were used for BoHV-1.1, 1.2,
and 5 VN and indirect ﬂuorescent antibody (IFA) assays, and
for competition ELISA (cELISA) assays. BoHV-1.1 VN titers
of ascites were 512–4096 and BoHV-1.1 IFA titers were
1600–3200. Three bovine polyclonal antisera were used as
controls: anti-BoHV-1 (produced using Cooper isolate) –
used as a positive control; anti-bovine viral diarrhea virus
(produced using 4 isolates); and anti-parainﬂuenza 3 virus.
The latter two  antisera had previously been demonstrated
to not react in VN or IFA assays with BoHV-1.1 and were
used as negative controls. A negative control ascites was
produced in BALB/c mice using the non-secreting murine
hybridoma SP2/0. All Ab preparations were stored frozen.
Prior to use, they were thawed, low-speed centrifuged to
clarify, heat treated (56 ◦C × 35 min) to inactivate C, and
stored at 4 ◦C. Other high-titered preparations of BomAb
(e.g., from hollow-ﬁber cultures, as described in Levings
et al., 2014) were used for some of the HV speciﬁcity assays.
The MumAb  conjugated and used in cELISA assays have
been described previously: D9, F2, G2, C11, G1 (Collins et al.,
1984); 4407, 4807, 5106, 5606, 1507, 1808, 2905, 3002,
6003, 1102, 1106, 3402, 4906, 5006 (Marshall et al., 1986);
1E11, 1F8, 1F10, 3F3, 5G2 (van Drunen Littel-van den Hurk
et al., 1985); 10C2, 3C1, 3E7, 9D6 (Hughes et al., 1988); and
3D9S (van Drunen Littel-van den Hurk and Babiuk, 1986).
2.3. Virus neutralization (VN) assays
The Madin Darby bovine kidney cell line, minimum
essential media with supplements (MEM), growth media,
and maintenance media as described (Levings et al., 2014)
were used for BoHV-1.1, 1.2, and 5 VN and IFA assays as
well as virus expansion.
Constant Ab-varying virus (alpha) VN assays were per-
formed using BoHV-1.1, 1.2, and 5. The virus preparations
described in section 2.1 were diluted 10−2 to 10−9 in
MEM with 2% guinea pig C. Equal volumes of each of Ab
preparation (neat, with MEM  as a negative control) and
each of the viruses were combined in microtiter plate
wells and incubated for 2 h at 37 ◦C. Standard cell culture
inoculation and incubation methods were used (Levings
et al., 2014). Cytopathology was read using light
microscopy (40×, 100×). Endpoint virus titers at day 6
post-inoculation were calculated using the Reed–Muench
method (Reed and Muench, 1938).
Equal-volume virus/Ab (screening) plaque-reduction
VN assays were performed using EHV-1, FeHV-1, and
CaHV-1. In each case the protocol and interpretation
followed the constant virus-varying Ab (beta) CVB Sup-
plemental Assay Method 119 (Anon., 2011) for SuHV-1,
another HV. Reagents appropriate to each virus were
substituted for SuHV-1 reagents, and a single dilution
of Ab (neat) was  used. Equine dermal cells, homologous
antiserum (positive control) and MEM  with 10% horse
serum (negative control) were used for EHV-1 assays.
Crandell feline kidney cells, 4-well (50 mm diameter)
plates, homologous antiserum (positive control), and
SP2/0 ascites and FBS (negative controls) were used by
CVB personnel for FeHV-1 assays. Madin Darby canine
kidney cells, homologous antiserum (positive control),
and SP2/0 ascites and FBS (negative controls) were used
by CVB personnel for CaHV-1 assays.
2.4. Indirect ﬂuorescent antibody (IFA) assays
Microtiter IFA assays were performed as described
(Levings et al., 2014). Plates were prepared using 100 ± 26
TCID50 per inoculum of BoHV-1.1, -1.2, and -5 viruses to
ensure infected and uninfected cells. MEM  was inoculated
into wells of the same plate as a negative virus control. Each
Ab preparation was diluted 1:100 in PBS for analysis, and
PBS was added to equivalent wells as a negative Ab control.
Ab incubation was 2 h at room temperature.
IFA assays with other viruses were performed using sim-
ilar methods, using cell cultures of the virus’ host species
or other permissive cultures. Direct conjugate (for HHV-1)
or homologous antisera with species-appropriate conju-
gates were used as positive controls. Heterologous BomAb
(anti-bovine parvovirus, as described in Levings et al., 2014)
preparations were used as negative controls for BoHV-2,
BoHV-4, and SuHV-1 assays. AlHV-1 and AlHV-2 assays
were performed by NVSL personnel using a 1:20 dilution of
BomAb nude mouse ascites and infected bovine turbinate
(for AlHV-1) or lamb kidney (for AlHV-2) cells. SP2/0 ascites
was used as a negative Ab control for AlHV-1 and AlHV-2
assays.
Conjugates used for all IFA assays were FITC-conjugated
anti-species Ig (e.g., anti-bovine Ig for BomAb and bovine
antiserum, anti-porcine Ig for porcine antiserum), rabbit
or goat origin, kindly provided by NVSL. Assays were read
using a mercury lamp ﬂuorescent microscope (130×) and
scored according to the intensity of the ﬂuorescence of
infected vs. uninfected cells (e.g., −, +, ++).
2.5. Competition ELISA (cELISA)
cELISA tests between horseradish peroxidase-
conjugated MumAb  and nude mouse ascites containing
each of the three BomAb were performed as described
(Ayers et al., 1989). Brieﬂy, BomAb ascites dilutions were
added to microtiter plates coated with 200 ng per well
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of puriﬁed BoHV-1. After a 30 min  incubation at 37 ◦C,
peroxidase-conjugated MumAb  was added without wash-
ing, and the plates were incubated for another 30 min  at
37 ◦C. Plates were then washed with TNE (0.05 Tris, 0.15 M
NaCl, 0.001 M EDTA, pH 7.2) containing 0.05% Tween
20. O-phenylenediamine (0.4 mg/ml) – 0.01% H2O2 in
citrate phosphate buffer (pH 5.0) was added as substrate.
The reaction was stopped with 2 N H2SO4, and the OD
at 492 nm (630 nm reference wavelength) was read. OD
was plotted vs. BomAb ascites dilution for reactions using
each of the MumAb  conjugates, and second order linear
regression performed. The ODs at select dilutions of
competing vs. non-competing MumAb  conjugates were
also compared.
2.6. Sequence comparisons of BoHV-1.1, BoHV-1.2, and
BoHV-5 gB, gC, and gD
Amino acid (aa) sequences for the entire gp, of epi-
topes or domains of interest, and of epitope-adjacent (EA)
regions were compared between the BoHV. Epitopes and
domains were as described in the literature (Fitzpatrick
et al., 1990; Tikoo et al., 1993; Abdelmagid et al., 1995,
1998; Chowdhury, 1997). 100 aa EA regions were ana-
lyzed for gB and 80 aa EA regions were targeted for gD.
The shorter gD regions were chosen for better symme-
try between amino- (EAN) and carboxy- (EAC) adjacent
regions, as one of the EA pair was truncated (<80 aa) due to
modeled sequence termini. A gC domain of interest and its
adjacent domains were analyzed.
The following aa sequences were accessed on UniPro-
tKB (http://www.uniprot.org/; Jain et al., 2009; UniProt
Consortium, 2010): BoHV-1.1 Cooper isolate gB (P12640),
gC (P14378) and gD (Q76PF1); BoHV-1.2 K-22 iso-
late gB (Q9Q0A6 partial sequence) and ST isolate gD
(Q08100); and BoHV-5 N565 isolate gB (Q9QAP7),
SV507/99 isolate gC (Q6X256) and TX89 (equivalent
to EC-2) isolate gD (Q65535). The aa sequence of
BoHV-1.2 K-22 isolate gC was accessed in Hecht et al.
(1995). Additional HV gD aa sequences were also
accessed from UniProtKB: SuHV-1 (Q8B3S6); EHV-1
(P24872); FeHV-1 (Q89634); CaHV-1 (O41524), and
HHV-1 (P57083). Sequence alignments were done using
ClustalW2 (Larkin et al., 2007) within UniProtKB, and lalign
(http://www.ch.embnet.org/software/LALIGN form.html;
Huang and Miller, 1991).
To examine potential antigenicity impacts of limited
sequence changes, hydrophilicity analyses were performed
on BoHV-1.1 and BoHV-5 gB and gD using an on-line
molecular toolkit (http://www.vivo.colostate.edu/molkit/
hydropathy/index.html; Bowen, 1998). Hopp–Woods
(Hopp and Woods, 1981) and Kyte–Doolittle (Kyte and
Doolittle, 1982) scales were used, with window sizes of
6 and 9, respectively. Plots were compared visually with
previously reported Kyte–Doolittle plots using a window
size of 9 (Abdelmagid et al., 1995; Ros and Belak, 2002).
2.7. Molecular modeling – target–template comparison
The homology and likenesses (including function,
sequence, hydrophobicity plots, and location of cysteines
and potential glycosylation sites) of HV including BoHV-
1.1, 1.2 and 5 gB, gC, and gD to those of HHV-1 have
been described (Whitbeck et al., 1988; Tikoo et al., 1990;
Heldwein et al., 2006; Hook and Friedman, 2007). The iden-
tity (and similarity) of BoHV gB and gD aa sequences and
those of HHV-1 were further examined to assess the reli-
ability of modeling the BoHV gB and gD on the HHV-1
gB and gD crystal structures (an HHV-1 gC crystal struc-
ture was not available). aa sequences for the entire gp, for
epitopes of interest, and for EA regions were compared
between each of the BoHV and HHV-1. The aa sequences for
BoHV were accessed as described in Section 2.6. Sequences
were accessed on UniProtKB for HHV-1 strain KOS gB
(P06437) and gD (P57083). Sequences were compared as
described in Section 2.6, with the addition of alignments
reported in the modeling output.
Further analysis of BoHV and HHV-1 gD similarities was
done due to the lower (<25%) sequence identity of the
gps. Solvent accessibility proﬁles (Rost and Sander, 1993)
for BoHV-1.1 and HHV-1 gD were generated using the
online PredictProtein program (www.predictprotein.org/;
Rost et al., 2003) and visually compared.
2.8. Molecular modeling – construction, quality metrics,
and analysis
The model for BoHV-1.1 gB was constructed
from the accessed aa sequence using SWISS-MODEL
(http://swissmodel.expasy.org/; Arnold et al., 2006; Kiefer
et al., 2009; Peitsch, 1995) in automatic mode (Arnold
et al., 2006; Schwede et al., 2003; Guex and Peitsch, 1997).
The program used the HHV-1 gB crystal structure 2GUM
(Heldwein et al., 2006) as a template for BoHV-1.1, and
3NW8 (Stampfer et al., 2010) as a template for BoHV-5.
The reports included alignments, overall composite quality
scores (Qmean; Benkert et al., 2011), and estimated residue
error (in A˚) by aa. Averages and ranges of aa errors, and aa
with errors >5.0 A˚ were calculated or noted for the epitopes
and EA of interest. The BoHV-1.1 and BoHV-5 gB models
constructed were visually compared to each other, to the
reported BoHV-5 gB model, and to the HHV-1 gB crystal
structures 2GUM and 3NW8 accessed at the Research
Collaboratory for Structural Bioinformatics protein data
bank (RCSB PDB) (http://www.pdb.org; Berman et al.,
2000). The reported BoHV-5 gB model (from Q9QAP7,
Ros and Belak, 1999) used 2GUM as a template and was
accessed from the SWISS-MODEL Repository (Kiefer et al.,
2009; Kopp and Schwede, 2004).
The models for BoHV-1.1 and BoHV-5 gC were
constructed from the accessed aa sequences using SWISS-
MODEL in automatic mode. The program used a variety of
Ig superfamily member crystal structure as templates for
segments of each. The gC models were visually examined,
as were the reported HHV-1 gC models (which used two
Ig crystal structures, 1A8J and 1F6A, as templates for seg-
ments) accessed from the SWISS-MODEL Repository. No
crystal structure for HHV-1 gC was  available from the RCSB
PDB.
The models for BoHV-1.1 gD, BoHV-1.2 gD, and BoHV-5
gD were constructed from the accessed aa sequences using
SWISS-MODEL in automatic mode. The program used the
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Fig. 1. BoHV-1-speciﬁc and non-speciﬁc neutralization1 by three BoHV-1.1-generated bovine mAb2 and controls. 1Reported in log10 virus neutralized per
0.025  ml inoculum, compared to the geometric mean of the two media control titers. Because the lowest virus dilution examined was  10−2, if none of the
wells  at any dilution evidenced virus infection, the highest possible titer of the preparation was  101.50. As a result, all neutralized titers over 4.00 are greater
than  or equal to the value shown. 2For explanation of virus, bovine mAb, and antiserum abbreviations please refer to notes for Table 1.
HHV-1 gD crystal structure 2C36 (Krummenacher et al.,
2005) as a template for each. Reports and the data derived
from them were as for gB. The gD models were visually
compared to each other, to reported models for each of
the same gp using the HHV-1 gD crystal structure 1JMA
(Carﬁ et al., 2001) as a template, and to the HHV-1 gD
crystal structures 2C36 and 1JMA accessed from the RCSB
PDB. The gD models reported for BoHV-1.1 (from Q76PF1,
Goltz et al., 2006), BoHV-1.2 (from Q08100, Leung-Tack
1994), and BoHV-5 (from Q6X200, Delhon 2003) were
accessed from the SWISS-MODEL Repository. RasMol ver-
sion 2.7.4.2 (http://rasmol.org/; Sayle and Milner-White,
1995; Bernstein, 2000) was used to visualize and analyze
all PDB ﬁles.
3. Results
3.1. Virus neutralization (VN) assays
Results of VN assays using each of the three BomAb
with each of the ﬁve bovine HV isolates are shown in
Fig. 1. gB-09 and gC-05 were speciﬁc for BoHV-1 isolates,
although gB-09 reacted weakly with BoHV-5 and results
varied between the BoHV-1 isolates. gD-16 neutralized all
bovine HV isolates completely, similar to BoHV-1 anti-
serum. The three BomAb were negative by VN to EHV-1,
FeHV-1, and CaHV-1 (results not shown).
3.2. Indirect ﬂuorescent antibody (IFA) assays
Results of IFA assays using each of the three BomAb
with ﬁxed cell cultures infected with each of the ﬁve
bovine HV isolates are shown in Table 1. gB-09 and
gC-05 were fundamentally speciﬁc for BoHV-1 isolates,
although gC-05 did react weakly with the BoHV-5 iso-
lates (and gB-09 reacted very weakly or non-speciﬁcally).
The gD-16 reacted strongly with all bovine HV isolates,
similar to BoHV-1 antiserum. When the three nude mouse
ascites were retested at higher concentrations (diluted 1:30
and 1:50 rather than 1:100), the reactivity was increased
slightly where it was  weak, but the differences were still
evident. A weak reaction was observed using gB-09 and
gC-05 with BoHV-4-infected cell cultures (possibly con-
sistent with the ﬁndings of Mohanty et al., 1984), but not
using gD-16 (results not shown). The three BomAb were
negative by IFA with BoHV-2, SuHV-1, and HHV-1 (results
not shown).
Table 1
Bovine herpesvirus 1 (BoHV-1) speciﬁc and non-speciﬁc reactionsa in
indirect ﬂuorescent antibody assays by three BoHV-1.1-elicited bovine
monoclonal antibodies.
BoHV-1.1 BoHV-1.2 BoHV-5 No virus
COb LAc K-22d EC-1e EC-2f CCg
gB-09h +++ +++ +++ +/− +/− −
gC-05i +++ +++ +++ + + −
gD-16j +++ +++ +++ +++ +++ −
BoHV-1 ASk +++ +++ +++ +++ +++ −
SP2/0l − − − − − −
BVD ASm − − − − − −
PI3 ASn +/− +/− +/− − − −
PBSo − − − − − −
a Intensity of the infected cell-speciﬁc ﬂuorescence: − negative; +/−
very weak/questionable; + weak; ++ moderate; +++ strong.
b BoHV-1.1 Cooper isolate.
c BoHV-1.1 Los Angeles isolate.
d BoHV-1.2 K-22 isolate.
e BoHV-5 EC-1 isolate.
f BoHV-5 EC-2 isolate.
g Uninfected cell control.
h Anti-BoHV-1.1 glycoprotein B bovine monoclonal antibody.
i Anti-BoHV-1.1 glycoprotein C bovine monoclonal antibody.
j Anti-BoHV-1.1 glycoprotein D bovine monoclonal antibody.
k Polyclonal bovine antiserum to BoHV-1.1.
l Ascites to (non-secreting) murine hybridoma SP2/0.
m Polyclonal bovine antiserum to bovine viral diarrhea virus.
n Polyclonal bovine antiserum to parainﬂuenza 3 virus.
o Phosphate buffered saline.
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Table 2
Competition by three anti-BoHV-1.1 bovine monoclonal antibodies (mAb) with panels of characterized murine mAb in an ELISA.
gB gC gD
Epitopea mAbb gB-09c competed Epitope mAb  gC-05 competed Epitope mAb  gD-16 competed
D9 − G1 − IV 1102 −
II  3F3 − C11 − 1004 −
II  4807 − V 1808 − 2 3E7 −
III  5606 − IV 3002 − I 5006 −
5306  − 6003 − II 1106 −
4407  − III 2905 − 3a 10C2 −
I  5106 − IX F2 − 3d 3C1 −
IVa  1F8 − G2 − III 4906 −
IVb  5G2 − 1507 − Ib 9D6 +
III  1E11 − 3402 +
V  1F10 + 3D9S −
a Epitope nomenclature varies with the source of mAb  and work done with each. System used here follows Collins et al. (1993).
b Order of mAb follows established epitope maps (Ayers et al., 1989) for each of the glycoproteins and deﬁnes overlapping and unique epitopes.
c For explanation of bovine mAb  identities please refer to notes for Table 1.
3.3. Competition ELISA (cELISA)
Results of cELISA assays using each of the three BomAb
with conjugated MumAb  speciﬁc for epitopes of gB, gC,
and gD are shown in Table 2. gB-09 competed with the
MumAb  conjugate 1F10. The ELISA OD at 1:50 ascites dilu-
tion was <50% of that with the non-competing MumAb
conjugate 3F3. The 1F10 epitope was previously local-
ized in mammalian cell transfection experiments to aa
380–440 of gB (Fitzpatrick et al., 1990). gC-05 did not
compete with any of the nine anti-gC MumAb  conjugates
tested. gD-16 competed with two MumAb  conjugates,
3402 and 9D6. The ELISA ODs at 1:50 ascites dilution were
<30% and <60% of non-competing MumAb  conjugate 3D9S,
respectively. Gene truncation experiments using an E coli
expression system mapped the 3402 epitope to BoHV-1.1
gD aa 52–126, and a peptide (aa 92–106) blocked 3402
binding (Abdelmagid et al., 1995). Gene truncation experi-
ments using a vaccinia expression system mapped the 9D6
epitope to aa 164–216 (Tikoo et al., 1993), but those using
a baculovirus expression system mapped it to aa 52–126
(Abdelmagid et al., 1998). The latter region would be iden-
tical to the 3402 epitope mapped using the E. coli system,
and would encompass the 3402-blocking peptide aa. Due
to the uncertainty and size of the 9D6 epitope location, the
3402 epitope was the exclusive focus of further analysis.
Table 3
BoHV-5 amino acid (aa) sequence identity with BoHV-1.1 (%) of select glycoproteins (gp), epitopes, and epitope-adjacent (EA) regions.a
gp Epitope or EAb region BoHV-1.1 BoHV-5 Comparison
gp aa No. of aa gp aa No. of aa Alignment positionsc BoHV-5% identity with
BoHV-1.1
gB Overall 1–932 932 1–947 947 948 92.3
Overall, LAlign 1–932 932 1–947 947 948 92.3
1F10  Epitope 380–440 61 387–447 61 61 91.8
EAN:1–100 280–379 100 287–386 100 100 98.0
EAC:1–50 441–490 50 448–497 50 50 94.0
EAC:51–100 491–540 50 498–554 57 58 46.6d
EAC:1–100 441–540 100 448–554 107 108 68.5d
gC Overall 1–521 521 1–486 486 522 74.7
Overall, LAlign 5–505 501 5–483 479 502 77.7
Domain 2e 22–150 129 22–129 108 130 41.5
Domain 1 1–21 21 1–21 21 21 71.4
Domain 3 151–260 110 130–239 110 110 88.2
gD Overall 1–417 417 1–417 417 417 79.9
Overall, LAlign 6–417 412 7–417 411 415 81.4
3402  Epitope 92–106 15 93–107 15 15 73.3f
EAN:1–73g 19–91 73 20–92 73 73 96.7h
EAC:1–80 107–186 80 108–187 80 80 91.2i
a For explanation of virus and glycoprotein abbreviations please refer to notes for Table 1.
b EA designations indicate amino (N) or carboxyl (C) adjacency and number of BoHV-1.1 aa from the epitope.
c All alignments done with ClustalW2 unless otherwise indicated.
d Includes an 8 aa insertion in BoHV-5 relative to BoHV-1.1.
e Domains are as deﬁned in Chowdhury (1997), and are numbered amino- to carboxy-terminal.
f All 4 mismatches are located in a 9 aa area (55.6% identity).
g This region includes the amino terminus of the mature protein (does not include the 18 aa signal sequence) – 80 structural aa were therefore not
available for comparison.
h The 34 aa adjacent to the epitope are 100% identical.
i The 17 aa adjacent to the epitope are 100% identical.
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3.4. Sequence comparisons of BoHV-1.1, BoHV-1.2, and
BoHV-5 gB, gC, and gD
Results of aa sequence alignment of BoHV-1 and 5
whole gp, epitope, and EA are shown in Table 3. BoHV-1.1
and BoHV-5 gB aa sequences demonstrated high iden-
tity (91–98%) overall, for the 1F10 epitope, and for the
100 aa EAN and 50 aa EAC regions. However, the region
1F10-EAC:51–100 showed much lower (46.6%) identity,
including an insertion of 8 aa for BoHV-5 relative to BoHV-
1.1. Only a partial (219 aa) BoHV-1.2 gB sequence was
available (aa 192–410 of BoHV-1.1), which covers all of
1F10-EAN:1–100, ∼50% (BoHV-1.1 aa 380–410) of the 1F10
epitope, and none of 1F10-EAC. It had 100% sequence iden-
tity with BoHV-1.1 over those aa.
BoHV-1.1 and BoHV-5 gC aa sequences were 74–78%
identical overall. Domain 2, previously identiﬁed as
immunologically differentiating BoHV-1 and 5, had much
lower identity (41.5%). Identities of adjacent domains 1
and 3 were similar to the overall gp identity. BoHV-1.1
and BoHV-1.2 sequences were 95–99% identical for gC (aa
1–505 for both viruses).
BoHV-1.1 and BoHV-5 gD aa sequences showed rela-
tively high (∼80%, LAlign score 2.7 e−228) identity overall
when aligned, although identity varied. Illustrative 50 aa
examples of the range of sequence identity between the
two viruses are BoHV-1.1 aa 41–90 (98.0%) and 281–330
(38.2%). The short 3402 epitope showed lower (73.3%) iden-
tity between the two viruses than overall, with EA regions
showing higher identity (>91%). The alignment of BoHV-1.1
and BoHV-1.2 gD aa showed sequences were 98.1% identi-
cal (aa 1–417 for both viruses).
Hydrophilicity plots for BoHV-1.1 and BoHV-5 gB and
gD are shown in Fig. 2. The plots for gB are nearly identical
between the two viruses for BoHV-1.1 aa ∼120–932 except
for 1F10-EAC 51–100 (BoHV-1.1 491–540). The plots for gD
are nearly identical between the two viruses for BoHV-1.1
aa 46–205 except for a more hydrophilic region centered
on aa 97 in BoHV-5. This is attributable to the difference in
aa hydrophilicity values (Hopp and Woods, 1981) between
BoHV-1.1 aa 94–99 VRRHAR (−1.5, +3.0, +3.0, −0.5, −0.5,
+3.0) and BoHV-5 aa 95–100 VRRNER (−1.5, +3.0, +3.0, +3.0,
+3.0, +3.0).
3.5. Molecular models – target–template comparison
and model quality
3.5.1. gB
Table 4 shows the aa identities to HHV-1 gB for each of
BoHV-1.1 and BoHV-5 gB were similar overall, in the area
modeled, and in the 1F10 epitope and EA regions. Iden-
tities for the entire molecule ranged from 47.0 to 50.5%
(LAlign scores 8.0–8.1 e−275), with the 1F10 epitope being
somewhat lower and 1F10-EAN somewhat higher. Simi-
larities (identical, conserved, and semi-conserved aa) for
the entire molecules (by ClustalW2) ranged from 76.2 to
76.8%. The alignments generated by each program were not
identical. The modeling program used internal 635–650 aa
sequences including the epitope of interest and the EAs.
The alignment report for the modeling was not complete
in the 1F10-EAC:1–100 area (although it was reported
as different between BoHV-1.1 and BoHV-5), so % iden-
tities could not be calculated for that region. However,
ClustalW2 alignment identities were similar to the 1F10
epitope (41%) for EAC:1–50 (40–42%) and much lower for
EAC:51–100 (22–26%), or 33% for EAC:1–100. The model-
ing alignments showed alignment of all 10 cysteines and
four of the ﬁve potential N-linked glycosylation sites in the
modeled range. The ClustalW2 and LAlign alignments show
insertions totaling 23 and 30 aa for BoHV-1 and BoHV-5
respectively between aa 470 and 500 of HHV-1 gB (within
1F10-EAC:1–100).
The quality assessment plot from SwissModel showed
good anolea scores for the epitope and EAN:1–100 regions,
with greater uncertainty for EAC:1–100 (data not shown).
Similar identity and model quality assessment results were
observed for the accessed BoHV-5 model. Local error scores
were similar in the epitope and EAN:1–100 regions to
those of the overall molecule, with much higher errors in
EAC:1–100. It should be noted that not only is the mod-
eling uncertainty higher in EAC:1–100, but BoHV-1.1 and
BoHV-5 have lower identity in that region, as well.
The Qmean scores were 0.486–0.505, and the average of
local errors over the entire model were 2.70–2.90 A˚.  How-
ever, the local error ranges extended from 0 to 10.35 and
10.64 A˚. In each case the maximum error was observed in
1F10-EAC:51–100, and that 50 aa included over half the aas
with errors >5.0 A˚ (26 of 50 for BoHV-1.1, and 20 of 38 for
BoHV-5). No aa with an error >5.0 A˚ was observed in the
1F10 epitope. The anolea scores reported for the reported
BoHV-5 (on 2GUM) model were similar but not identical to
those of the models constructed on 2GUM in this study.
3.5.2. gC
The models generated for BoHV-1.1 and BoHV-5 gC
were fragmentary (≤210 aa), based on non-gC templates
of low identity (≤27%, e.g., 11% for a 207 aa sequence),
and did not include structurally amino-terminal domain
2. The models accessed for HHV-1 gC were incomplete
and similarly based on non-gC templates of low iden-
tity. Comparisons were not performed due to the resultant
low conﬁdence in results, the lack of a MumAb  epitope
sequence for examination, and the lack of model coverage
of the domain of interest.
3.5.3. gD
Table 5 shows the aa identities to HHV-1 gD for each
of BoHV-1.1, 1.2, and 5 gD were similar overall, in the
area modeled, and in the epitope of interest. The EAN
region identities were lower, and EAC identities higher,
than the overall identities. The alignments generated by
each program were not identical. Identities for the entire
molecules ranged from 21.8 to 29.1% (LAlign scores 5.6
e−23 to 4.6 e−21). Similarities for the entire molecules
(by ClustalW2) ranged from 47.4 to 49.1%. The modeling
alignments showed alignment of all 6 cysteines and the
one potential N-linked glycosylation site in the modeled
range. The ClustalW2 alignment showed an insert of 18 aa
for HHV-1 relative to BoHV-1.1, 1.2, and 5 before BoHV-
1.1 aa 42, and inserts totaling 31 aa in BoHV-1.1, 1.2, and
5 relative to HHV-1 after BoHV-1.1 aa 251. The modeling
program used internal 234–254 aa sequences which
186 R.L. Levings et al. / Veterinary Immunology and Immunopathology 164 (2015) 179–193
Fig. 2. Hopp–Woods hydrophilic plots of BoHV-1.1 and BoHV-5 gB (A) and gD (B), by amino acid position, using a 6 amino acid window. On the plots,
hydrophilic = positive values, hydrophobic = negative values.
included the 3402 epitope, but limited the size of the EAN.
The identity levels and local errors were different for the
80 aa EAC and 61 aa EAN.
The solvent access plots for BoHV-1.1 and HHV-1 gD
were very similar (data not shown), particularly in the
regions of BoHV-1.1 aa 1–213 and HHV-1 aa 1–227,
encompassing the cysteine–cysteine bonds of each virus.
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Table  4
BoHV gB amino acid (aa) sequence identity (%ID) with human herpesvirus 1 (HHV-1) of select gps, epitopes and EA regions.a
ClustalW2 LAlign SWISS-MODEL
Overall Overall Overall 1F10 Epitope EAN:1–100 EAC:1–50 EAC:51–100 EAC:1–100
BoHV-1.1b
% ID with HHV1 50.5 49.0 48.0 41.0 61.0 NAvc NAv NAv
No.  positions 940 904 638 61 100 50 50 100
BoHV-1.1 aa 1–932 29–928 122–756 380–440 280–379 441–490 491–540 441–540
HHV-1  aa 1–904 25–896 110–724 369–429 269–368 430-? ?-506 430–506
aa  errord average NAe NA 2.90 2.61 2.16 3.68 6.03 4.75
aa  error range NA NA 0–10.35 1.52–4.67 0.54–4.94 0.46–7.46 3.93–10.35 0.46–10.35
BoHV-5f
% ID with HHV1 47.0 49.5 48.5 41.0 63.0 44.0 NAv NAv
No.  positions 954 882 650 61 100 50 50 100
BoHV-5 aa 1–947 66–943 121–770 387–447 287–386 448–497 498–547 448–547
HHV-1  aa 1–904 47–896 103–724 369–429 269–368 430–473 474–499 430–499
aa  error average NA NA 2.70 2.47 1.83 2.74 5.21 3.96
aa  error range NA NA 0–10.64 1.68–4.11 0–3.92 0.611 3.41–10.64 0–10.64
a For explanation of virus, glycoprotein, epitope, and epitope-adjacent regions, please refer to notes for Tables 1 and 3.
b Modeled using HHV-1 crystal structure 2GUMB.
c Not available, see text for ClustalW2% identities.
d Estimated per-residue inaccuracies in A˚.
e Not applicable.
f Modeled using HHV-1 crystal structure 3NW8D.
However, the C–C pairings predicted were different for the
two viruses using the program.
The Qmean scores for the models were 0.373–0.419,
and the average aa error over the entire model was
2.98–3.15 A˚. However, the local error range extended
from 0 to 8.67 A˚. In each case the maximum error was
observed within 3 aa of a terminus of the modeled region.
aa (0–5) with errors >5.0 A˚ were found in the epitope
regions. Notably, within the 3402 epitope aa 95–98 of
BoHV-1.1 and 1.2 were over 5.0 A˚, but the homologous
aa 96–99 of BoHV-5 (of the models constructed here)
were not.
Table 5
BoHV gD amino acid (aa) sequence identity (%ID) with human herpesvirus 1 (HHV-1) of select gps, epitope and EA regions.a
Clustal LAlign SWISS-MODEL
Overall Overall Overall 3402 Epitope EAN:1–80 EAC:1–80
BoHV-1.1b
% ID to HHV-1 22.6 28.7 23.6 26.7 19.7 36.2
No.  positions 438 251 254 16 61c 80
BoHV-1.1 aa 1–417 46–292 31–272 92–106 31–91 107–186
HHV-1  aa 1–394 63–306 48–307 108–123 48–107 124–202
aa  error ave.d NAe NA 3.15 3.34 3.61 2.02
aa  error range NA NA 0–6.85f 0.24–5.63 2.15–6.77f 0–3.63
BoHV-1.2
%  ID to HHV1 23.4 29.1 25.6 25.0 18.0 37.5
No.  positions 438 251 234 16 61c 80
BoHV-1.2 aa 1–417 46–292 31–262 92–106 31–91 107–186
HHV-1  aa 1–394 63–306 48–276 108–123 48–107 124–202
aa  error ave. NA NA 2.98 3.34 3.60 2.03
aa  error range NA NA 0–6.39f 0.23–5.64 2.02–6.39f 0–3.68
BoHV-5
%  ID to HHV-1 21.8 26.9 24.4 31.2 21.3 36.2
No.  positions 435 286 254 16 61c 80
BoHV-5 aa 1–417 47–330 32–273 93–107 32–92 108–187
HHV-1  aa 1–394 63–341 48–296 108–123 48–107 124–202
aa  error ave. NA NA 3.12 3.47 3.73 1.97
aa  error range NA NA 0–8.67f 0.30–6.08 2.06–6.81f 0–3.81
a For explanation of virus, glycoprotein, epitope, and epitope-adjacent regions, please refer to notes for Tables 1 and 3.
b BoHV-1.1, 1.2, and 5 were modeled using HHV-1 crystal structure 2C36.
c Modeled sequence did not extend 80 aa from the epitope.
d Average of estimated per-residue inaccuracies in A˚.
e Not applicable.
f Maximum local error observed within 3 aa of model terminus
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Fig. 3. Ribbon models of BoHV-1.11 gB (a) and BoHV-5 gB (b) based on the HHV-1 gB crystal structure 2GUM. The amino acids corresponding to the carboxyl
region of domain II of HHV-1 are represented in green. The virus envelope would be to the bottom of each model, and the other two  protomers of the gB
trimer would be to the left. 1For an explanation of virus, glycoprotein, and epitope-adjacent region abbreviations please refer to notes for Tables 1 and 3.
HHV-1 = human herpesvirus 1.
3.6. Molecular models – comparisons and analysis of
exposed aa
The models generated for BoHV-1.1. and BoHV-5 gB
were similar to each other, to the reported BoHV-5 model,
and to the HHV-1 crystal structures 2GUM and 3NW8, with
the exception of the 1F10-EAC:1–100 region. The model
generated for BoHV-1.1 gB based on crystal structure
2GUM is shown in comparison with the model accessed
for BoHV-5 gB (also based on crystal structure 2GUM)
in Fig. 3, in ‘ribbon mode’ for ease of domain and region
visualization. The model localized the 1F10 epitope to an
alpha-helix structure on the exterior of the gp trimer. The
locations of the ﬁrst and last aa of the 1F10 epitope, as well
as representative aa of 1F10-EAC:51–100 are labeled in the
ﬁgure. In the BoHV-1.1 model and HHV-1 crystals, the EAC
region is arranged in -helices (HHV-1) or less structured
(BoHV-1.1) areas, and separated from the epitope region
(farther away from the virion envelope). In BoHV-5 models,
the EAC region looks similar, but depending on the model
was separate or was shifted toward the virion envelope in
BoHV-5, partially covering the epitope. A useful marker for
this change is aa 493 in BoHV-1, corresponding to aa 500 in
BoHV-5. The model constructed here for BoHV-5 gB (based
on the crystal structure 3NW8) more closely resembled
BoHV-1.1 in this region, and the crystal structure 3NW8
included an alpha-helix which did not cover the 1F10
homologous region.
The fragmentary models generated for BoHV-1.1 and
BoHV-5 gC (data not shown) were not compared to each
other or to the incomplete models of HHV-1 gC accessed.
The models generated for BoHV-1.1, 1.2, and BoHV-5 gD
were similar to each other and to the reported BoHV-1.1,
1.2, and BoHV-5 gD models except for slight differences in
the ‘apex’ of the models (area distal from the viral envelope,
see BoHV-1.1 Arg 95). The models generated for BoHV-1.1,
BoHV-1.2, and BoHV-5 gD based on HHV-1 gD crystal struc-
ture 2c36 are shown in Fig. 4, in ‘spaceﬁll’ mode to illustrate
surface vs. internal aa. Select aa of the 3402 epitope and
adjacent hairpin turns are labeled on the BoHV-1.1 model
to illustrate the aa of those turns exposed to the surface
of the molecule. The BoHV-1.1 gD model indicates that aa
81–102, 124–160, and 180–183 are exposed, and on adja-
cent hairpin turns of the globular protein.
The ClustalW2 sequence alignment of the gD aa corre-
sponding to the aa observed on the models to be exposed
and adjacent to the 3402 epitope of BoHV-1.1, BoHV-1.2,
BoHV-5 (the viruses reacting with gD-16), as well as those
of several HV not reacting with gD-16 in this study is
shown in Fig. 5. BoHV-1.2 and BoHV-5 aa sequence identity
with BoHV-1.1 is >75% in those regions. The aa sequence
identity with BoHV-1.1 for the other viruses studied is
<52%.
4. Discussion
This study examined the BoHV reactivities of three neu-
tralizing BomAb raised to BoHV-1.1 and compared them
to those of well-characterized MumAb  that competed in
ELISA. Epitope, sequence, and modeling information was
then used to further explain the results.
4.1. gB
The BomAb gB-09 reacted strongly in VN and IFA with
BoHV-1.1 and BoHV-1.2, but very weakly with BoHV-5. It
competed with one MumAb  in the panel, 1F10. 1F10 had
previously been shown to neutralize BoHV-1.1 strongly but
not to neutralize BoHV-5. However, it reacted in radio-
immunoprecipitation (RIP) with both viruses (Collins et al.,
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Fig. 4. Spaceﬁll models of BoHV-1.11 gD, BoHV-1.2, and BoHV-5 gD, based on the HHV-1 gD crystal structure 2c36. The virus envelope would be to the top
of  each model. 1For an explanation of virus and glycoprotein abbreviations please refer to notes for Table 1. HHV-1 = human herpesvirus 1.
1993). So while the VN activity of the bovine and murine
competing mAb  matched, the RIP/IFA activity did not.
1F10 has a wide variety of activities with BoHV-
1.1 (van Drunen Littel-van den Hurk et al., 1984, 1985,
1990a,b; Ayers et al., 1994). The 1F10 epitope was local-
ized in mammalian cell transfection experiments to aa
380–440 of BoHV-1.1 gB. The aa sequence included cys-
teines, potential N-glycosylation sites, and the predicted
Fig. 5. Alignment of the glycoprotein D (gD) amino acid sequences of various assayed alphaherpesviruses1 for the areas exposed in bovine herpesvirus
(BoHV) 1.1 gD, demonstrating the differences in degrees of identity with BoHV-1.1. Amino acid identity with BoHV-1.1 is designated by bold and underline.
Numbering is according to BoHV-1.1 sequence. 1SuHV-1 = suid herpesvirus 1, EHV-1 = equid herpesvirus 1, FeHV-1 = felid herpesvirus 1, CaHV-1 = canid
herpesvirus 1, HHV-1 = human herpesvirus 1.
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secondary structure included -helices and beta-sheets
(Fitzpatrick et al., 1990). The aa sequences and hydrophilic-
ity/hydrophobicity plots for the 1F10 epitope are similar
between BoHV-1 and 5, but those for the EAC region are
not (Whitbeck et al., 1988; Ros and Belak, 2002).
When modeled, the epitope was localized to an alpha-
helix on the exterior of the molecule. The alpha-helix
nature of the epitope might explain the loss of 1F10 ELISA
reactivity when the gB protein was denatured (van Drunen
Littel-van den Hurk et al., 1984), and why peptides of
the BoHV-1.1 gB 380–440 region did not elicit an ELISA
response in calves (Gao et al., 1999). The possible steric
hindrance produced by glycosylation at the potential N-
glycosylation site at N441 could explain the improved 1F10
ELISA reactivity when gB was de-glycosylated (van Drunen
Littel-van den Hurk et al., 1990a).
When modeled, EAC conformation varied and in at
least one BoHV-5 model the EAC physically covered the
conserved the 1F10 epitope. A covering of the epitope
in BoHV-5 but not BoHV-1.1 could explain 1F10 binding
BoHV-1.1 in both RIP and VN, but binding BoHV-5 only in
RIP (solubilized protein), not VN (native conﬁguration).
The BoHV reactivity of gB-09 could then be explained
in one of two ways. The gB-09 epitope may  be the same as
the 1F10 epitope. gB-09 would fail to react with BoHV-5
if its gB was in a native conﬁguration in both VN and IFA
assays, and would compete with 1F10. Alternatively, the
gB-09 epitope may  be located on the 1F10-EAC region.
The sequence differences would explain its failure to react
with BoHV-5 in either assay, and the physical proximity
of BoHV-1.1 1F10-EAC to the 1F10 epitope would explain
gB-09 competition with 1F10.
4.2. gC
The BomAb gC-05 reacted strongly in IFA with
BoHV-1.1 and BoHV-1.2, but weakly with BoHV-5. It
neutralized only BoHV-1, although neutralization varied
among the isolates. This is difﬁcult to explain considering
the extremely high gC identity of the three isolates (BoHV-
1.1 and 1.2 sequences are 98.0% identical over the BoHV-1.2
sequence, with no clusters of differences). gC-05 did not
compete with any of the MumAb  in the panel. The com-
plete gC aa sequences of BoHV-1.1, BoHV-1.2, and BoHV-5
(and HHV-1) are known, but no crystal structure for HHV-1
gC has been published.
However, some studies of strain antigenic differences
related to sequence and secondary structure have been per-
formed. BoHV-1.1 gC has been described as having seven
domains, from the amino-terminal signal peptide (domain
1) to the carboxy-terminal cytoplasmic tail (domain 7),
including domains 3–5 with homology to the Ig super-
family (Chowdhury, 1997). BoHV-1.1- and BoHV-5-speciﬁc
MumAb  and bovine antisera have been demonstrated
against domain 2 (BoHV-1.1 aa 22–150), which ‘constitutes
a long uninterrupted hydrophilic domain’ (Chowdhury,
1995; 1997). Domain 2 was 41.5% identical between BoHV-
1.1 and BoHV-5 in this study (much lower than the rest of
the protein), and glycosylation sites did not align. The low-
est identity was noted in BoHV-1.1 aa 31–122 (25.8%), with
inserts totaling 21 aa in BoHV-1.1 relative to BoHV-5. Of
ﬁve anti-BoHV-1.1 MumAb  whose epitopes were localized
to domain 2 (Fitzpatrick et al., 1990; Chowdhury, 1995),
only two  (F2 and 24) were directed against sites of virus
neutralization, and they were speciﬁc for BoHV-1.1 (Collins
et al., 1993; Chowdhury, 1995). The MumAb  epitopes were
mapped to BoHV-1.1 aa 47–69 (F2), and 109–119 (24)
(Chowdhury, 1997). MumAb  F2 did not compete with gC-
05 in this study.
Although BoHV-1.1 and BoHV-5 are not 100% identical
in other domains (making it possible for virus-speciﬁc epi-
topes to be located there), the results of this study suggest
gC-05 may  be directed against an epitope on BoHV-1.1 aa
22–150, excluding 47–69.
4.3. gD
The BomAb gD-16 reacted strongly in VN and IFA
assays with BoHV-1.1, BoHV-1.2, and BoHV-5. It competed
with two  MumAbs in the panel, 3402 and 9D6 (3402 more
strongly). Both 3402 and 9D6 had previously been shown
to react in VN and RIP with BoHV-1.1, but not to react
in RIP with BoHV-5 gD (and so were not tested by VN)
(Collins 1993). Thus, the RIP/IFA and presumably the VN
reactivity of the bovine and murine competing mAb  did not
match.
3402 has a wide variety of activities with BoHV-1.1
(Marshall et al., 1988; Dubuisson et al., 1992; Ayers et al.,
1994). It was suggested 3402 and 9D6 react with the same
epitope (Collins et al., 1993). The 3402 epitope was local-
ized to BoHV-1.1 aa 52–126. A peptide within the mapped
region (aa 92–106) designed to include a BoHV-1.1/BoHV-5
divergent sequence blocked 3402 binding, and elicited a VN
response in rabbits (Abdelmagid et al., 1995). The 92–106
region of BoHV-1.1 was  predicted from the aa sequence to
be hydrophilic (Tikoo et al., 1990).
BoHV-1.1, 1.2, and 5 gD were modeled from a crys-
tal structure of HHV-1 gD to further examine exposure
and adjacency characteristics of identical and divergent
sequences related to the putative epitope of 3402. It
should be noted that neither the complete amino-terminal
strand thought to bind cellular receptors, nor the complete
carboxy-terminal strand thought to bind to gB or gH/gL was
included in the HHV-1 crystal structures or the BoHV mod-
els presented. Both strands are known to adhere to the
exterior of the globular structure included in the crystal
structures and models. It is therefore possible some of the
aa observed to be exposed in the model are actually covered
by other gD areas. Although gD is a dimer, the dimer crystal
2c36 does not indicate close proximity of the protomers in
the ‘exposed areas’ described here.
Examination of the BoHV-1.1 gD model revealed aa
81–102 of the mapped 3402 epitope 52–126 are exposed on
the exterior of the molecule. This includes aa 92–102 of the
identiﬁed peptide 92–106, and includes a 9 aa (aa 92–100)
region within the 3402 epitope of lower identity (55.6%)
between BoHV-1.1 (and the identical BoHV-1.2) and BoHV-
5. That region includes the 2 aa (aa 97–98) contributing to
the hydrophilicity plot difference between BoHV-1 and 5.
The ≥23 aa both amino- and carboxy-adjacent to the 9 aa
low-identity region are 100% conserved between BoHV-1.1
and BoHV-5.
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The exposed 11 aa area BoHV-1.1 81–91, which is 100%
conserved among BoHV-1.1, BoHV-1.2, and BoHV-5 (gD-
16 positive), but only 9.0–63.6% conserved with other HV
tested (gD-16 negative), suggests a possible gD-16 epi-
tope that could explain both competition with 3402 (due
to proximity) and the BomAb’s reactivity with all BoHV-1
and 5 isolates but not other HV.
Another hairpin turn exposed and adjacent to the
3402 epitope at the envelope-distal end of the globular
gD structure consists of BoHV-1 aa 124–160. If gD-16
reacted with this area - highly conserved between BoHV-
1.1 (and the identical BoHV-1.2) and BoHV-5, but not other
HV – it might also explain the BomAb’s competition
with the MumAb  (through steric inhibition) as well as its
strain/virus reactivity. The 4 aa BoHV-1.1 180–183, with
one aa difference between BoHV-1.1 (and BoHV-1.2) and
BoHV-5 could potentially also explain or contribute to gD-
16’s reactivity.
The mechanism of neutralization of antibodies directed
to the regions at the distal end of gD are not clear.
The region is not implicated in binding cellular receptors
or binding other viral glycoproteins to trigger envelope-
membrane fusion (Whitbeck et al., 1999; Connolly et al.,
2005). It is possible a mAb  binding to the globular
part of gD would prevent the conformational change
that results from cellular receptor binding (and results
in release of the carboxy-strand to bind gB or gH/gL),
but the mechanism of neutralization remains to be fully
described.
4.4. Summary
The three BoHV-1.1-neutralizing BomAb studied did
not react to an appreciable degree with other HV infect-
ing cattle (including BoHV-2, BoHV-4, SuHV-1, AlHV-1 and
AlHV-2), and had differing proﬁles in their reactivity with
the ﬁve bovine HV isolates studied. Two (gB-09 and gC-
05) had different reactivities between BoHV-1.1/BoHV-1.2
and BoHV-5, and if this pattern were conﬁrmed with addi-
tional isolates of each, would be useful in bovine Ab assays
differentiating the viruses. gD-16 recognized all three
bovine HV, and so would be useful in pan-bovine HV
Ab assays, should the pattern be conﬁrmed with additional
isolate testing.
The epitope speciﬁcity of the anti-gB BomAb appeared
to align to some degree with that of the competing MumAb,
but necessitated a tertiary structure explanation of each of
their strain speciﬁcities. The epitope speciﬁcity of the anti-
gC BomAb could only be speculated upon from aa sequence,
due to the lack of competing MumAb  and modeling tem-
plate structures. The virus strain speciﬁcity of the anti-gD
BomAb did not agree with that of the competing MumAb.
This suggested the BomAb targets an adjacent, conserved
sequence area. Use of peptides in binding or competition
assays could further elucidate the epitopes of gB-05, gC-
09, and gD-16 if they are linear.
The results suggest caution should be used when inter-
preting polyclonal host Ab competition with mAb, and
when MumAb  epitope identity alone is used in vaccine
design. The studies demonstrate the potential usefulness of
combining in vitro immunological and virological activity
data with sequence and modeling data in epitope investi-
gations.
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